Trials / Conditions / Platinum-refractory Ovarian Carcinoma

Platinum-refractory Ovarian Carcinoma

9 registered clinical trials studyying Platinum-refractory Ovarian Carcinoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without B NCT06393751	National Cancer Institute (NCI)	Phase 1 / Phase 2
Recruiting	A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957	NiKang Therapeutics, Inc.	Phase 1
Terminated	A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921	NiKang Therapeutics, Inc.	Phase 1
Withdrawn	Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent NCT05295589	National Cancer Institute (NCI)	Phase 2
Recruiting	Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Peg NCT05271318	TILT Biotherapeutics Ltd.	Phase 1 / Phase 2
Active Not Recruiting	Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents NCT04739800	National Cancer Institute (NCI)	Phase 2
Unknown	Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) NCT04678102	Seoul National University Hospital	Phase 1
Completed	Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With NCT03508570	M.D. Anderson Cancer Center	Phase 1
Completed	Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors NCT02835833	University of Alabama at Birmingham	Phase 1